NCT03479268
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 17 versions: 15 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 85 words Show 4 more changesShow less
- Trial completed
- Primary and study completion dates changed from estimate of Nov 5, 2026 to Oct 28, 2026
- Secondary endpoints: details revised at 2 of 2 entries
- Publications: details revised at 1 of 1 entry
- Notable Start date: Mar 22, 2018 to Apr 27, 2018v16
- Notable Primary and study completion dates: Nov 6, 2025 to Nov 5, 2026v15
- Minor Primary and study completion dates: Jun 22, 2025 to Nov 6, 2025v14
- Notable Primary and study completion dates: Dec 22, 2024 to Jun 22, 2025v13
Show 9 earlier versionsHide 9 earlier versions
- Notable Primary and study completion dates: Jun 22, 2024 to Dec 22, 2024v12
- Notable Primary and study completion dates pushed to Jun 22, 2024v11
- Notable Primary completion date: Apr 1, 2023 to Dec 1, 2023
- Study completion date: Apr 2, 2023 to Dec 2, 2023
Notable Primary completion date: Apr 1, 2022 to Apr 1, 2023v9 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 30 to confirmed 18
- Study completion date: Apr 2, 2024 to Apr 2, 2023
- Study sites revised (2)
- Notable Lead sponsor: OHSU Knight Cancer Institute to City of Hope Medical Center
- Study title shortened, about 2 words
- Notable Trial status: Active, Not Recruiting to Recruiting
- Enrollment target: 10 to 30
- Site details revised at 2 of 2 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 30 to confirmed 10
- Study description shortened, about 9 words
- Site details revised at 2 of 2 sites
- Minor Study sites: 1 to 2v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 1, 2018 to Mar 22, 2018
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
Drugs: Ibrutinib, Pevonedistat
Other: Laboratory Biomarker Analysis, Pharmacokinetic Study, Pharmacological Study
Sites
2 sites in 1 country